Search research articles
Contact Us
Filters
Showing results (81-90 of 89) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 89 results.
Journal of Hematology & Oncology
|
December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells
Michele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Nature Medicine
|
January 15, 2025
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Concetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.
Nature Medicine
|
February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
Marco Becilli, Markus Metzler, Claudia Bracaglia, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Emmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
The New England Journal of Medicine
|
April 5, 2023
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Francesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.
Blood Advances
|
August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AML
Swati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Nature Communications
|
December 15, 2023
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57<sup>Kip2</sup> targeting
Silvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 89) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 89 results.
Journal of Hematology & Oncology
|
December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells
Michele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Nature Medicine
|
January 15, 2025
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Concetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.
Nature Medicine
|
February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
Marco Becilli, Markus Metzler, Claudia Bracaglia, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Emmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
The New England Journal of Medicine
|
April 5, 2023
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Francesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.
Blood Advances
|
August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AML
Swati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Nature Communications
|
December 15, 2023
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57<sup>Kip2</sup> targeting
Silvia Pomella, Matteo Cassandri, Lucrezia D'Archivio, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Page
of 9